H.R. 7291 · 119th Congress
GRAS Oversight and Transparency Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Not yet voted on. This bill is still a proposal: it hasn't reached a floor vote, and its text can change in committee or on the floor before any vote.
R
LawlerSponsor1 cosponsor · 1 D
0 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill requires the Food and Drug Administration (FDA) to establish a board to review determinations made by food manufacturers prior to the year 2000 that certain substances are safe for use in food.
What it does: CRS summary · Introduced in House · Jan 30, 2026
GRAS Oversight and Transparency Act
This bill requires the Food and Drug Administration (FDA) to establish a board to review determinations made by food manufacturers prior to the year 2000 that certain substances are safe for use in food.
Under current law, substances added to food must generally be approved by the FDA. However, substances that are generally recognized as safe (GRAS) by qualified experts are exempt from the FDA's premarket review. Manufacturers are not required to notify the FDA when they designate a substance as GRAS.
Under the bill, each food manufacturer must provide the board with a list of pre-2000 GRAS designations attributable to the manufacturer. Manufacturers who do not comply may be subject to specified penalties. The board must review each designation and notify Congress and the FDA of (1) a determination that a substance has not been shown to be safe, and (2) a recommendation that the FDA revoke a GRAS designation.
After receiving such a notification, if the FDA decides to revoke the GRAS designation, it must notify the manufacturer and provide them an opportunity to offer evidence of the substance’s safety. The FDA must review its revocation decision using such evidence. The FDA must also establish procedures to ensure compliance with a revocation, including a timeline for recalling and ceasing distribution of substances.
The board must report to the FDA and Congress with information about reviews carried out under the bill.
The bill terminates 10 years after enactment.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: GRAS Oversight and Transparency Act
Latest action (Jan 30, 2026): Referred to the House Committee on Energy and Commerce.
Policy area: Health · Origin: House · Introduced: Jan 30, 2026
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.